Bayer's Rapeseed Biofuel Pivot Meets a Pharma Pipeline Finally Pulling Its Weight

Barclays lifted its Bayer target to EUR 70 as the group sealed a Neste rapeseed biofuel deal and won FDA approval for Hyrnuo in HER2-mutant NSCLC.

Bayer spent this week doing what it has done for much of the year: stacking up catalysts across two very different businesses. On Wednesday the Leverkusen group unveiled a commercial agreement with Finnish refiner Neste to scale its newgold® winter rapeseed for biofuel production, a move that slots agriculture squarely into the energy transition. A day earlier, Barclays had raised its price target on the stock from EUR 60 to EUR 70 while keeping an Overweight rating — the most bullish call among major houses, with J.P. Morgan at EUR 61 and UBS at EUR 62.

The market's response was muted. Bayer shares changed hands at EUR 47.87 on Friday, down 1.3% on the day and 2.0% over the week, leaving the stock below its 50-day average of EUR 48.56. Zoom out, though, and the picture shifts: the equity is up 29% year-to-date and 66% over twelve months, and it still sits comfortably above its 200-day line of EUR 42.13 — roughly 15% higher, and about 9.7% shy of the 52-week peak of EUR 53.86.

Rapeseed as the Bridge Between Farm and Fuel

The Neste tie-up targets a niche Bayer increasingly treats as strategic: agricultural raw materials destined not for plates but for renewable energy feedstocks. Under the arrangement, newgold® winter rapeseed is meant to strengthen biofuel supply chains, with Neste acting as the buyer and processor. It is the latest in a string of Crop Science announcements, following recent progress updates on Plenexos™ and the Preceon™ Smart Corn System, plus cost-saving targets for the agricultural division communicated about a week ago.

Oncology forms the second leg of the growth story, and it delivered its own headline midweek. The FDA granted accelerated approval to sevabertinib — marketed as Hyrnuo — as a first-line therapy for adults with a specific form of non-small cell lung cancer driven by activating HER2 mutations, a group estimated at 2% to 4% of NSCLC patients. The nod, dated 9 September, came just after a separate approval notice for a Bayer product had weighed on the shares. Bayer calls the drug a key building block of its oncology portfolio.

The clinical data behind the decision carry weight. In the SOHO-01 trial, 69 previously untreated patients showed a 75% reduction in tumor size, with 73% of responders holding that response for at least six months. Kerendia, meanwhile, posted a 75% revenue increase in the first half.

The Numbers Behind the Bull Case

Operating momentum has caught up with the pipeline narrative. In the second quarter Bayer swung from a loss of EUR 0.20 per share a year earlier to a profit of EUR 0.23 per share, on revenue that edged up to EUR 10.87 billion. Consensus looks for earnings of EUR 4.53 per share in 2026 — the kind of trajectory that makes Barclays' EUR 70 target look less like a stretch and more like a logical extension, provided the stock can clear its prior high of EUR 53.86.

Barclays grounds its upgrade in an operational recovery across pharma — carried by Kerendia and Hyrnuo — and agriculture, alongside fading risks from glyphosate litigation. That last point is the swing factor. The bank points to a Missouri settlement framework worth up to USD 7.25 billion as evidence the legal overhang is becoming quantifiable. Whether that template holds for the remaining pending cases is the question investors cannot yet answer. If new settlements or rulings keep the cost burden predictable, attention can migrate to the operating business. If a ruling goes the wrong way, the risk premium snaps back into the price quickly.

What Could Derail the Story

Hyrnuo's safety profile is one brake on the commercial ramp. In the registration study, diarrhea hit 89% of patients, 16% of them severely, and a third of participants experienced serious adverse events overall. Such tolerability data can slow uptake even after approval.

Macro conditions add another layer. The DAX logged a notable weekly loss, pressured by an oil price shock tied to the Iran conflict and expectations of further rate moves from the ECB and the Fed. When risk appetite sours broadly, even fundamentally sound single names come under pressure regardless of their own news flow.

The next hard checkpoint arrives with third-quarter results, scheduled for 3 November. Until then, the market's focus will be on whether other analysts drift toward Barclays' more optimistic view — or whether the caution of J.P. Morgan and UBS, with their lower targets, remains the prevailing line. For now, Bayer offers investors two distinct engines: a research-heavy pharma arm fresh off another regulatory win, and an agricultural business extending its product range toward the energy transition. Set against the twelve-month performance, the recent softness reads more like a breather than a warning.